Ramasastry Saira 4
4 · Sensei Biotherapeutics, Inc. · Filed Jun 16, 2026
Research Summary
AI-generated summary of this filing
Sensei Biotherapeutics Director Saira Ramasastry Receives 25,000-Share Award
What Happened
Director Saira Ramasastry was granted a derivative award covering 25,000 shares of Sensei Biotherapeutics (FTH) on June 12, 2026. The award shows a $0.00 acquisition price (no immediate cash outlay reported). This is an award/grant (code A) rather than an open-market purchase or sale.
Key Details
- Transaction date: June 12, 2026; filing date: June 16, 2026 (timely filing).
- Instrument: Derivative award/grant covering 25,000 shares; reported acquisition price $0.00.
- Vesting: 36 equal monthly installments over three years; fully vested on June 12, 2029, contingent on continuous service (per footnote).
- Shares owned after the transaction: Not specified in the filing.
- Filing status: Timely (filed within required reporting window). No 10b5-1 plan, tax-withholding, or sale reported in this filing.
Context
This was a compensation award to a director rather than a market purchase or sale. Such grants are commonly used for director compensation and become economically meaningful only as they vest (or are exercised/settled) and any associated taxes are handled. The filing does not indicate any immediate sale or exercise of underlying shares.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-12+25,000→ 25,000 totalExercise: $13.00Exp: 2036-06-11→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.